Research Insights
Evidence-based analysis of peptide research. Research digests unpack landmark studies; trend reports surface cross-peptide patterns; evidence briefs deliver fast reads on single questions.
Does Medicaid Cover Wegovy or Zepbound for Weight Loss? A State-by-State Guide for 2026
As of October 5, 2026, we could confirm that nine state Medicaid programs still pay for GLP-1 drugs prescribed for weight loss. Seven states ended that coverage this year, and Delaware's status is unclear. This guide lists each state's status, what Medicaid must still cover, and what to try if your state dropped the benefit.
GLP-1 Drugs for Weight Gain From Antipsychotics: The Trials, the Risks, and How to Ask
Many people who take antipsychotics such as clozapine or olanzapine gain weight and develop diabetes or heart risks. Randomized trials show GLP-1 drugs like liraglutide and semaglutide can reverse part of that weight gain without making psychiatric symptoms worse. This guide covers the evidence, the side effects to watch, and how to raise it with your care team.
GLP-1 Drugs and Your Eyes: NAION, Diabetic Retinopathy, and Retinal Blockages
Three different eye conditions come up in discussions of Ozempic, Wegovy, Mounjaro, and Zepbound. One is a rare optic nerve problem, one is a temporary worsening of diabetic eye disease when blood sugar falls fast, and one may become less common on these drugs. This guide explains each, how strong the evidence is, and what to do if your vision changes.
Peptides and GLP-1 Drugs After Cancer: What Survivors Should Know
Cancer survivors are asking about GLP-1 weight-loss drugs and wellness peptides like BPC-157 and growth hormone boosters. The evidence on GLP-1s is growing; for growth-signal peptides, the concerns come from biology, and direct studies in survivors do not exist. Here is what is known and what to ask your oncology team.
Ozempic Face: Why GLP-1 Weight Loss Changes Your Face and What Can Limit It
"Ozempic face" is a nickname, not a diagnosis, for the hollow cheeks and looser skin some people notice after losing weight on semaglutide or tirzepatide. Imaging studies suggest it mostly reflects how much weight is lost, not the drug itself. This guide covers what the studies measured, who is more likely to notice it, what may help, and what cosmetic treatments can and cannot do.
Which GLP-1 Drug Is FDA-Approved for What: Weight, Diabetes, Heart, Kidneys, Sleep Apnea, and Liver
Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo, and the other GLP-1 drugs each carry their own FDA-approved uses, and insurers pay by those uses. One table from the current labels, the uses added since 2024, the age limits, and why the label decides coverage.
Buying Retatrutide or Zenagamtide Online: What Lab Tests and Hospital Cases Show
Neither drug is approved anywhere, but dozens of websites sell them. Australian lab tests found vials with half or nearly twice the labeled dose, and one with a different drug entirely. Here are the hospital cases so far, what the trials found, and what the law says.
Do Ozempic and Zepbound Slow Aging? Reading Lilly and Novo's Aging-Clock Data
At a Harvard aging meeting in October 2026, Novo Nordisk and Eli Lilly said semaglutide and tirzepatide lowered molecular measures of biological age. How the clocks work, what each company measured, why a lower score is not the same as a longer life, and what the outcome trials show.
Icotyde for Psoriasis: How the First Peptide Pill Compares With Shots and Other Pills
Icotyde (icotrokinra), approved by the FDA in March 2026, is a once-daily pill that blocks the same immune pathway as the psoriasis shots Skyrizi and Tremfya. It beat the pill Sotyktu in two head-to-head trials but has not yet been tested directly against any injection. This guide covers the trial results, the daily routine, the safety label, and the cost.
Peptides for Ulcerative Colitis and Crohn's Disease: An IL-23 Pill in Phase 3, GLP-2 Drugs, and the BPC-157 Gap
The peptide with the strongest case in inflammatory bowel disease is icotrokinra, a once-daily pill now in Phase 3 trials for both ulcerative colitis and Crohn's disease. This guide covers what its earlier trial showed and which gut peptides are already approved, and it explains where gray-market claims fall short.
Peptides for Osteoporosis: Teriparatide, Abaloparatide, Calcitonin, and an Oral Bone Builder in Testing
Two FDA-approved peptides build new bone and cut spine fractures in trials, and teriparatide now comes in generic form. This guide covers who qualifies, why the order of treatment matters, what the drugs cost, and where calcitonin and BPC-157 fit.
Why Your Resting Heart Rate Goes Up on Wegovy, Zepbound, and Other GLP-1 Drugs
GLP-1 drugs raise resting heart rate by a few beats per minute on average, and a smartwatch can show a bigger jump. The label data, the biology, the large heart trials, the newer glucagon drugs, and the signs that need a doctor's attention.
The 2026 Diabetes Consensus Backs GLP-1 or SGLT2 Drugs Early, Possibly From Diagnosis, Without Waiting on Metformin
The American Diabetes Association and the European Association for the Study of Diabetes published their first joint treatment report since 2022 on October 2, 2026. A patient's guide to the changes, from weight targets to heart and kidney protection, and the questions to bring to your next appointment.
GLP-1 Users Reported Lifting Nails Four Times as Often as Nonusers: The Evidence on Hair and Nail Changes
A self-reported survey presented at EADV 2026 found more nail detachment, discoloration, and hair shedding among GLP-1 users. The rates run far above those in the Wegovy and Zepbound trials, and no study has shown that the drugs cause them.
Novo's Study Favored Novo, Lilly's Study Favored Lilly: How to Read a Drug-Company Comparison
At EASD 2026, a claims analysis and an indirect comparison each favored the sponsor's drug. A guide to what those designs can prove, what randomized head-to-head trials add, and which fine print to read first.
The FDA's Empower Letter and the 'Essentially Copies' Rule for Compounded Semaglutide and Tirzepatide
A September 18, 2026 warning letter to Houston's Empower Pharmacy says its compounded GLP-1s look like copies of approved drugs, made in large volumes and backed by copy-and-paste prescription notes. Here is the rule behind the letter, why the end of the shortages matters, and what patients on compounded GLP-1s should ask.
Peptide Radioligand Therapy: How Lutathera and Pluvicto Work, Who Qualifies, and the Supply Chain Behind Every Dose
Lutathera for neuroendocrine tumors and Pluvicto for advanced prostate cancer carry radiation straight to cancer cells, and in September 2026 the FDA approved two more lutetium-177 dotatate products for the same tumors as Lutathera. On September 21, 2026, Telix agreed to merge with ITM, which Telix calls the only producer of commercial-grade lutetium-177 at global scale. Supply is the part of this story patients feel most.
Chills, Cycle Changes, and Fatigue: Side Effects Penn's AI Found in 400,000 Reddit Posts From GLP-1 Users
A University of Pennsylvania Engineering team published in Nature Health an analysis of 410,198 Reddit posts from 67,008 self-reported semaglutide or tirzepatide users. Reproductive symptoms and body-temperature complaints came up more often than the drug labels would suggest. This piece walks through what the study found, why the hypothalamus is a plausible common thread, why Reddit is not a substitute for a clinical trial, and what to ask your prescriber if you notice any of these symptoms.
Tirzepatide vs Semaglutide: 4.3 Percentage Points More Weight Loss, Higher Serious Adverse Event Rate, Across 10 Head-to-Head Studies of 41,381 Adults
A systematic review and meta-analysis of head-to-head comparisons — three randomized controlled trials and seven retrospective cohort studies covering 41,381 adults with overweight or obesity — landed in Diabetes, Obesity and Metabolism and drew Medscape coverage the week of September 8, 2026. Tirzepatide (Mounjaro / Zepbound) produced a mean 4.28 percentage points more weight loss than semaglutide (Ozempic / Wegovy) and about 4.4 kg (9.7 lbs) more absolute weight loss. Serious adverse events were rare in both arms but showed up somewhat more often on tirzepatide. This piece walks through what the pooled data show, how the numbers translate to real-world choice, and where the safety trade-off, price, and insurance rules should probably tip your decision.
Semaglutide in Children Aged 6-11: Novo STEP Young Phase 3 Results, Safety, and the Timeline to Possible Approval
STEP Young reported that 40.4% of children aged 6 to under 12 dropped below the obesity threshold at week 68 on semaglutide plus lifestyle changes, versus 0% on placebo. Wegovy is not approved in the United States below age 12, and Novo Nordisk has not announced a filing. This piece walks through the trial results, what safety data we do and do not have, the current pediatric-obesity treatment landscape, cost and insurance realities, the ethical debate, and questions to bring to your pediatrician.
Monthly GLP-1 Injections: What's in Development, When They'll Arrive, and Whether Switching From Weekly Is Worth It
Amgen's MariTide, Pfizer's MET-097i, and several other monthly GLP-1 candidates are working through late-stage trials. This piece walks through why manufacturers are chasing monthly dosing, which candidates are in development, the real convenience-versus-efficacy trade-offs, and how to think about switching once monthly options reach the market in 2027-2028.
GLP-1 Weight Loss and Lean Mass: What the Studies Show
GLP-1 weight-loss studies measure changes in fat and lean tissue. Lean mass is not the same as skeletal muscle, and separate trials do not establish a muscle-preservation ranking.
TrumpRx and the January 2026 GLP-1 Price Cut: A Buyer's Guide to $245 Wegovy, $149 Pills, and Real Out-of-Pocket Costs
The November 2025 pricing agreement between the Trump administration and Eli Lilly plus Novo Nordisk cuts GLP-1 prices for Medicare, Medicaid, and direct-to-consumer purchases starting January 2026. This piece walks through the price you pay under each type of coverage, when the changes take effect, how TrumpRx works, and what compounded-GLP-1 users should be thinking about.
Muscle Preservation on GLP-1s: What UCN2, Amylin, and GIP Add for Body Recomp
Body-composition studies show that both fat and lean tissue can decrease during weight loss. The published evidence does not establish a muscle-preservation ranking for semaglutide, tirzepatide, retatrutide, and emerging UCN2 therapies.
Glutathione IV Drips, Oral Pills, and Injections: The Bioavailability Gap Between Formats
Oral and liposomal studies measure changes in glutathione stores, but do not establish a universal absorption percentage or a best delivery format for health outcomes.
Real-World Weight Loss on Ozempic and Wegovy: The 5-12% You Might Get Versus the 15% in the Trials
Semaglutide's registrational trial (STEP-1) reported 14.9% mean weight loss at 68 weeks. Real-world registry and claims analyses report 5.9% to 12% at 6 to 12 months for the same drug in the same doses. This piece walks through what the trials measured, what real-world data shows, why the gap exists, who tends to respond better, and what a buyer can actually expect.
Wegovy 7.2 mg: The Higher-Dose Semaglutide Under FDA Review at Roughly 19% Weight Loss
Novo Nordisk has a higher-dose version of Wegovy under FDA review. Semaglutide 7.2 mg once weekly (up from the currently-approved 2.4 mg maximum) produced roughly 19% weight loss in the Phase 3 STEP UP trial, versus roughly 15% for the current 2.4 mg dose. This piece walks through what STEP UP showed, where the FDA review stands, how tolerability changes at higher doses, and how Wegovy 7.2 mg compares to Zepbound and retatrutide for current Wegovy users considering an intensification.
Retatrutide 28.7% and Ribupatide 23.6%: The Triple-Agonist Obesity Race Heading Into 2027
Two obesity drugs now hit three receptors at once — GLP-1, GIP, and glucagon. Eli Lilly's retatrutide filed the highest weight-loss number ever recorded in a Phase 3 trial. Kailera and Hengrui's ribupatide is behind but coming with an oral formulation. This piece walks through what a triple agonist is, why the third receptor matters, where the trials stand, and how the race is likely to play out into 2027 and 2028.
Setmelanotide (IMCIVREE) and Melanotan II: Same Peptide Family, Different Regulatory Worlds
One is an FDA-approved rare-disease drug that recorded 400 patient starts in six weeks. The other is a gray-market tanning peptide that regulators in Australia, the UK, and the EU tell people to avoid. Both are made from almost the same starting parts. This piece walks through the two molecules in plain language and uses the story to explain how a molecule becomes an approved drug in the first place.
CagriSema Lost to Tirzepatide by 2.5 Percentage Points at 84 Weeks. The Amylin Bet Didn't Pay Off.
Novo Nordisk's REDEFINE 4 trial pitted CagriSema (cagrilintide plus semaglutide) against Eli Lilly's tirzepatide over 84 weeks. CagriSema reached 23.0% weight loss. Tirzepatide reached 25.5%. The primary non-inferiority endpoint missed. This piece walks through the two mechanisms, why the GIP add-on beat the amylin add-on in this setup, what that says about retatrutide's triple agonist, and where it leaves CagriSema's commercial path.
Melanotan II Goes to the FDA Advisory Panel in February 2027
The FDA's Pharmacy Compounding Advisory Committee will review melanotan II in February 2027 for possible inclusion on the Section 503A bulks list. Melanotan II is currently sold gray-market as a tanning peptide and appetite suppressant. This piece walks through what the peptide is, what the safety record looks like, why regulators in other countries have warned against it, and what the FDA vote would actually change.
Arrowhead Paid $215 Million for a Priority Review Voucher. The Return Math Depends on Three Things.
In August 2026, Arrowhead Pharmaceuticals disclosed it paid $215 million for a Priority Review Voucher to shorten its plozasiran severe hypertriglyceridemia review from ten months to six. Management projects a 3x return. This piece walks through what a PRV is, where the secondary market has priced them, why Arrowhead thought this one worth the price, and when the math actually works for a buyer.
The Compounded Tirzepatide Problem: The B12 Chemistry Study Found Novel Molecules in the Vials
A 2026 chemistry study documented that compounded tirzepatide combined with vitamin B12 can chemically bond and form a new molecule that does not exist in the FDA-approved Zepbound or Mounjaro. Vitamin B12 is the most common additive that compounding pharmacies use to distinguish their products from the Eli Lilly branded tirzepatide. That distinction matters. This piece explains what compounding pharmacies do with B12 in these formulations, what the chemistry study found, why the FDA cited findings of this kind in its July 30, 2026 rulemaking to permanently exclude the branded GLP-1 molecules from the Section 503B Bulks List, and what patients on compounded tirzepatide should think about right now.
Fatigue on GLP-1s: The Fixes That Move the Needle on Ozempic, Wegovy, Mounjaro, Zepbound, and Foundayo
Extreme tiredness is one of the most common complaints from people on GLP-1 receptor agonist therapy: Ozempic (semaglutide), Wegovy (semaglutide, injection or pill), Mounjaro (tirzepatide), Zepbound (tirzepatide), Rybelsus (oral semaglutide), Foundayo (orforglipron), Trulicity (dulaglutide), and Saxenda (liraglutide). The fatigue is usually not random. It has specific mechanistic causes and a set of evidence-based interventions that most patients can work through with their prescriber. This piece walks through why GLP-1 receptor agonists cause fatigue, how to rule out red flags, what nutrition, training, hydration, and sleep changes actually help, and what to think about peptides that get marketed for energy and recovery in the wellness channel.
The GLP-1 Eye-Safety Signal: NAION Cases Cluster Around Semaglutide, Not Tirzepatide
On July 25, 2026, Australia's Therapeutics Goods Administration (TGA) updated the labels of every GLP-1 receptor agonist sold in the country with a new warning about non-arteritic anterior ischaemic optic neuropathy (NAION), a rare eye condition that can cause permanent vision loss. The TGA Advisory Committee on Medicines reached a specific conclusion: current evidence supports the signal for semaglutide (Ozempic, Wegovy), but not for dulaglutide (Trulicity) or tirzepatide (Mounjaro). This piece explains what NAION is, what the Australian action actually says, how the drug-specific split came out of the data, and what patients on GLP-1 therapy should know.
The Oral GLP-1 Landscape Is a Three-Horse Race: Foundayo (Orforglipron), the Wegovy Pill (Oral Semaglutide), and AstraZeneca's Elecoglipron (Phase 3 Just Launched)
For most of the GLP-1 era, oral GLP-1 meant one thing: Novo Nordisk's Rybelsus (oral semaglutide, launched 2019) for type 2 diabetes. That changed in 2025-2026. Novo launched the Wegovy pill (oral semaglutide, up to 25 mg daily, for obesity) in January 2026 after FDA approval in December 2025 based on the OASIS 4 trial. Eli Lilly received FDA approval of Foundayo (orforglipron), the first small-molecule oral GLP-1 receptor agonist, for weight management in April 2026. And on Monday July 27, 2026, AstraZeneca confirmed on its Q2 2026 earnings call that elecoglipron, the oral small-molecule GLP-1 that AstraZeneca licensed from Shanghai-based Eccogene, has moved into a full Phase 3 program across the EMBOLD (obesity) and ELUMINATE (type 2 diabetes) trials plus cardiovascular and kidney outcomes studies. This piece walks through what the three oral GLP-1 options look like today, what the head-to-head data shows, and how patients should think about the choice.
Teens on GLP-1s: Bariatric Surgery Down Three-Fold, GLP-1 Monotherapy Now 96% of Adolescent Obesity Treatment (JAMA Pediatrics)
On July 20, 2026, JAMA Pediatrics published a UT Southwestern Medical Center retrospective cohort study analyzing 204,000+ US adolescents and young adults ages 13-25 treated for obesity between May 2022 and January 2026 in the Epic Cosmos electronic health record database. The headline finding: the share of patients using only GLP-1 receptor agonist drugs rose from 88.2% (May-November 2022) to 96.1% (June 2025-January 2026), while the share of patients undergoing metabolic and bariatric surgery (MBS) fell from 11.6% to 3.7%. This piece walks through what the study actually measured, what the trend means for families making decisions today, what the study doesn't answer, and questions parents and teens should bring to a pediatric or adolescent-medicine appointment.
The FDA Panel Voted Yes on BPC-157 and KPV. Compounding Is Still Not Legal Today.
On July 23, 2026, an FDA advisory committee voted 8-6 with one abstention to recommend adding BPC-157 to the Section 503A compounding list. Later the same day, the panel voted identically to recommend KPV. Coverage all afternoon suggested peptides are now legal to prescribe. They aren't. This piece explains what the vote actually does, what still has to happen at the FDA, and when the real timeline for changed access lands.
The First Oral PCSK9 Inhibitor Just Got Approved. LIPFENDRA (Enlicitide) Sits Next to Your Statin, Not in Place of It.
On July 16, 2026, the FDA approved Merck's LIPFENDRA (enlicitide), the first once-daily oral pill in a drug class that had been injection-only since 2015. The drug is a macrocyclic peptide that survives your stomach and gets absorbed intact. It lowered LDL cholesterol by 56-59% in two Phase 3 trials. Merck priced it at $315 per month, roughly one-third the cost of the injectable competitors. This piece walks through what PCSK9 is, why oral matters, and what to think about if you or someone you know is on a statin.
IgA Nephropathy Got Two New Drugs in Ten Days. Trutakna and Fabhalta Do Different Things to Different Targets.
Vera Therapeutics' Trutakna won FDA approval on July 7, 2026. Novartis's Fabhalta won a full FDA approval on July 17. Both treat the same rare kidney disease that affects roughly 140,000 Americans. They work through very different biology and measure success against different endpoints. This piece walks through what each drug does, what the trial data actually showed, and what to ask a kidney doctor if either might be an option for you.
Medicare Launched GLP-1 Coverage. Your Employer Probably Still Won't Cover It.
The Medicare GLP-1 Bridge started July 1, 2026. Novo Nordisk cut prices. Employer coverage of GLP-1s for weight loss still sits at 36%, the same as last year. This piece walks through the numbers, the reasons, and what it means if you are on a GLP-1 or want to start.
Who's Really Selling Your Peptides? What Chainalysis Traced in the Gray Market
Blockchain analysts followed the crypto payments US buyers send to online peptide vendors. Some of those wallets used to sell fentanyl precursors. In the first three months of 2026 alone, $27 million in gray-market peptide crypto moved through a network that partly overlaps with the illegal drug trade. Here is what that means for anyone buying peptides online.
China's GLP-1 Export Machine: How the Obesity Pipeline's Biggest Deals Now Start in China
Positive obesity-pill data out of China on July 7 was one data point in a larger shift. A third of global drug-licensing dollars in early 2025 chased Chinese molecules, and obesity is the hottest category.
Beyond the Weekly Shot: The Race to Put GLP-1s in Implants and Patches
A twice-yearly semaglutide implant and a needle-free weekly patch both took real steps forward in mid-2026. The history of this exact idea says the device is the hard part.
The BPC-157 Analog Development Race: Fixing the Half-Life Problem Before It Reaches the FDA
Original BPC-157 clears the blood in under 30 minutes and has no completed Phase 2 trial after 30 years of research. Several biotechs are racing to build BPC-157 analogs with longer half-lives, better absorption, and the human safety data that would win FDA approval. Here is who's working on what.
Generic Tirzepatide: When Will Zepbound Get Cheaper?
Sandoz filed the first US application for generic Mounjaro and Zepbound. The FDA accepted the applications on June 29, 2026, more generic makers followed, and Lilly sued 14 of them in August. Federal law blocks final approval until about November 2029 unless the generic makers win in court, and Lilly's main patent runs to 2036. Here is what that means for prices at the pharmacy counter, the Medicare Bridge, and the broader GLP-1 market.
The 2026 Peptide Telehealth Landscape: Hims, LifeMD, Henry Meds, Ro, Pep Club, NohoLabs, and How to Pick
Half a dozen online platforms now prescribe and ship peptides to your door. They look similar on the outside. Under the hood, they source from different pharmacies, offer different peptides, charge different prices, and handle quality control very differently. Here is what each one actually does, and how to choose.
The FDA's Briefing Documents on Each of the Seven Peptides Going to PCAC
Career-staff scientists concluded ahead of the July 23-24 vote that none of the seven substances (BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon) has sufficient evidence for the 503A bulks list. Here is what the briefing actually says about each one, what FDA tested in compounded product samples, and where the strongest and weakest cases sit.
The PCAC Panelist Conflicts Map: Who FDA Named Monday and What They Sell
FDA published the names of eight new Pharmacy Compounding Advisory Committee panelists on Monday June 29. At least seven of the eight have ties to peptide-related businesses and clinics. Here is what the named members do for a living, what FDA conflict-of-interest rules require, and how this panel composition compares to previous PCAC reviews.
The Medicare GLP-1 Bridge: A Patient Guide to the July 1, 2026 Launch
Eligible Part D beneficiaries pay $50/month for Foundayo, Wegovy (injection or tablet), or Zepbound KwikPen through December 31, 2027. Who qualifies, how to apply through your doctor and pharmacy via Humana, what is covered, and what is not.
The AI Peptide Drug-Discovery Deal Map: Where the 2026 Capital Is Flowing
Six anchor deals from November 2025 through June 2026 totaled more than $9 billion in committed-and-contingent value. Chai-Lilly, Parabilis-Regeneron, Unnatural Products-Novartis, Insilico-SK Biopharm, Biogen-Dayra, Pinnacle Series B. Here's what each company actually does, and what the deal flow says about the next twelve months.
How to Evaluate a Compounding Pharmacy: 503A vs 503B, USP Standards, COAs, and What to Ask
If PCAC opens the door for BPC-157, TB-500, KPV, MOTS-c, and friends on July 23-24, prescription compounding becomes the legal supply path. Here is how to tell a real pharmacy from a research-chemical site in a lab coat: the regulatory tiers that matter, the USP standards that govern preparation, what a real Certificate of Analysis looks like, and the questions a good pharmacy will answer without flinching.
The July 23-24 PCAC Peptide Vote, Explained: What Happens to BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon
Seven peptides go to a Pharmacy Compounding Advisory Committee vote four weeks from now. The FDA's final call follows the vote but does not have to follow it. Here's what each peptide is, what the evidence looks like, and what 'yes' and 'no' mean for compounding pharmacies, Hims & Hers, and the gray market.
Peptides for Wrinkles: What the Human Trials Show
Matrixyl, Argireline, and copper peptides have different evidence bases. Results depend on the formulation, comparator, and outcome studied.
Compassionate Use and Obesity Drugs: What the Retatrutide Mystery-Patient Case Reveals
FDA grants 1,800+ expanded-access requests a year and approves 99% of them. Almost none are for obesity. The June 2026 retatrutide case is the rare exception, and the political fallout is louder than the precedent.
Peptides for Spinal Cord Injury and Stroke Recovery: Phase 3, Gray Market, and the Evidence Map
NervGen NVG-291 heads to Phase 3 in chronic tetraplegia mid-2026. Cerebrolysin: 50-country approval, no US. BPC-157 and TB-500 forum threads outrun the data.
Peptides for Dogs: Veterinary Treatments and the Limits of BPC-157 Evidence
Cytopoint has canine clinical trial evidence. The BPC-157 spinal-cord study cited here used rats. Those are different evidence bases for a dog owner to weigh.
Peptides for Erectile Dysfunction and Male Sexual Health: PT-141, Vyleesi, and the Evidence Map
PT-141 (bremelanotide) is FDA-approved for women, used off-label in men. Melanotan II shares the receptors with worse safety. The honest evidence map.
Peptides for Lower Back Pain: BPC-157, TB-500, and the Evidence Map
BPC-157 and TB-500 dominate the forum claims. Lilly's retatrutide chronic low back pain Phase 3 is the strongest evidence anyone has. Here's the honest map.
What Happens If Your Job Drops GLP-1 Coverage in 2027
A June 2026 survey found 1 in 10 large employers plan to stop covering Wegovy, Zepbound, and Foundayo next year. Here's the price map if that includes you.
Weight Loss Drugs and Bone Health: The New Fracture and BMD Data
Doctors worried weight loss from Ozempic and Wegovy would weaken bones. A new Stanford study tracking 161 million patients found the opposite.
What Doctors Are Learning About GLP-1s and Male Fertility
Men on Ozempic and Wegovy have been asking about testosterone and sperm. New ENDO 2026 data reverses what most people feared.
The Race to Bring Back a Hormone Most People Have Never Heard Of
PTH keeps blood calcium steady. At ENDO 2026 in Chicago, three peptide companies (Ascendis, MBX, Entera Bio) showed three different ways to replace it.
The Two Worlds of GHK-Cu: How a $32 Serum and a Restricted Injectable Are the Same Molecule
Cosmetic GHK-Cu sells freely at Ulta. Injectable GHK-Cu sits in FDA limbo ahead of a 2027 PCAC vote. The split is regulatory, not chemical.
Monthly GLP-1: Why Pfizer, Amgen, and Ascletis Are Stretching the Dose Interval
Two thirds of weekly GLP-1 patients quit within a year. The race to a monthly injection is a bet that adherence, not efficacy, decides the next decade.
The Amylin Wave: How a Forgotten Diabetes Hormone Became Obesity's Second Pillar
Pramlintide flopped in 2005. Forty amylin programs and $19B in deals have now turned the class into the GI-tolerant counterweight to GLP-1.
Ozempic for Kidney Disease: What the FLOW Trial Changed
Semaglutide became the first GLP-1 approved for chronic kidney disease in January 2025. What the FLOW trial showed, what the label covers, what's still open.
GLP-1s and Surgery: When to Stop Ozempic Before Anesthesia, and Why the Rule Changed
The 2023 advice was simple: stop the drug. By 2024 the major societies reversed it. Here is what the evidence actually shows and what to do before a procedure.
GLP-1s, Pregnancy, and Birth Control: The 'Ozempic Babies' Guide
Why surprise pregnancies happen on these drugs, the tirzepatide-pill interaction that semaglutide does not share, and how long to stop before trying to conceive.
May 2026 in Peptides: TRIUMPH-1, the Maintenance Pivot, and the First HDV Drug
Retatrutide's 28.3% ceiling, Novo's oral GLP-1 lead, ECO's maintenance pivot, EASL MASH and HBV-cure data, and bulevirtide's first HDV approval.
Microdosing Ozempic: The Reddit Trend, the Off-Label Doses, and the Missing Evidence
Sub-label GLP-1 dosing went from Reddit to a Rebel Wilson ad in eighteen months. The pharmacology is unfriendly and the compounding market drives the trend, and an August 2026 nference analysis of about 1,800 patients, reported by Healthline, put real-world numbers on it: about 2.2% weight loss at a year on low-dose semaglutide and 5.5% on low-dose tirzepatide.
Which MASH Drug for Which Patient: A Plain-English Guide for 2026
Two years ago there were zero approved drugs for MASH, the serious form of fatty liver disease. Now there are two — Rezdiffra and semaglutide (Wegovy) — and a wave of others is close behind. EASL 2026 in Barcelona this week brought fresh data on most of them: survodutide in the NEJM, pemvidutide's 48-week results, Aligos and Akero and the rest. Here's a plain-English guide to what's available, what's coming, and how doctors are starting to match the right drug to the right patient.
Beyond GLP-1 Alone: Why Combination Therapy Is the Next Obesity Breakthrough
Single-drug GLP-1 therapy hit a ceiling at about 28-30% weight loss with retatrutide. The next jump probably won't come from another solo drug. It'll come from pairing GLP-1s with other mechanisms. EASL 2026 in Barcelona gave the strongest evidence yet: Arrowhead's experimental RNAi drug ARO-INHBE doubled weight loss and tripled fat reduction when added to a small dose of tirzepatide. Here's why combination therapy is becoming the next frontier in obesity and MASH, and what's coming.
GLP-1s and Cancer: The 2026 Evidence Map Across Colorectal, Pancreatic, Breast, and Thyroid
GLP-1 drugs have been linked to modestly lower rates of obesity-related cancers and, in a 2026 study, to less cancer spread, but nearly all the evidence is observational. A guide to the data on prevention, treatment, and thyroid and pancreatic risks, as of October 2026.
GLP-1s vs Bariatric Surgery: How to Think About the Choice in 2026
Bariatric surgery procedures dropped below 200,000 in 2024 — the first time since 2020 — as GLP-1 prescriptions grew from 4,600 in 2018 to 1.4 million in 2025. Wegovy 14.9%, Zepbound 22.5%, Wegovy HD 20.7%, and retatrutide 28.3% now overlap substantially with sleeve gastrectomy (25-30%) and Roux-en-Y gastric bypass (30-35%). Here's what the comparison actually shows, where surgery still wins, where pharmacology now wins, and how to think about your own decision.
The Dysesthesia Signal: Why Retatrutide Tingles, and the Nerve-Fiber Question Behind It
About 20.9% of participants on retatrutide 12 mg reported dysesthesia in both the TRIUMPH-1 full ADA 2026 readout and the earlier TRIUMPH-4 trial — abnormal skin sensations that didn't appear in the tirzepatide or semaglutide development programs. The signal traces to retatrutide's third receptor arm: glucagon. Here's what the trial data showed, the most-likely mechanism, why the effect is dose-dependent, and how prescribers should think about it ahead of the 2027 approval window.
Should I Wait for Retatrutide? What TRIUMPH-1's 28.3% Phase 3 Readout Just Changed About Obesity Prescribing
Eli Lilly released TRIUMPH-1 Phase 3 topline May 21: retatrutide produced 28.3% mean weight loss at 12 mg over 80 weeks, 30.3% in the 104-week BMI ≥35 extension, and 45.3% of participants reached ≥30% weight loss — bariatric-surgery territory. The NDA filing is now Q4 2026 / Q1 2027, with TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (obesity + cardiovascular disease) still pending later this year. Here's what the readout means for patients deciding between starting Wegovy or Zepbound now and waiting for retatrutide.
GPR119 Agonists: The Indirect GLP-1 Strategy Pharma Is Trying Again
Sanofi paid $375M for the lead GPR119 agonist MBX-2982 in June 2010 and walked away by May 2011. The receptor is supposed to make your gut release its own GLP-1 — and fifteen years of failed development have made that simple idea quietly contentious. MetaVia's vanoglipel posted Phase 2a MASH data at AASLD in November 2025 and lands three late-breaking posters at ADA 2026 on June 7. Here's what GPR119 actually does, why the first wave of programs failed, and what's different this time.
NK2R: The Next Obesity Receptor After GLP-1?
Novo Nordisk paid €470M for an NK2R startup in 2023. The Nature paper landed in November 2024. Tsinghua's 2026 AI peptide design competition has now picked NK2R as the benchmark target. Here's what the receptor actually does, why it could avoid the nausea problem that limits GLP-1 adherence, and the realistic timeline to clinic.
$28/Year Generic Semaglutide Is Already Possible And It Won't Reach US Patients Until 2032
A March 2026 medRxiv preprint priced generic injectable semaglutide at $28-140/person-year, and Canada, India, and Brazil are already running with that math. US patent protection on the active drug runs through December 2031. The catch isn't manufacturing — it's device patents, policy coordination, and Novo's preemptive 2027 list-price cut.
EASO First-Line: The New Obesity Treatment Algorithm by Complication, Explained
The European Association for the Study of Obesity published an updated treatment framework in Nature Medicine on May 14, 2026, formally privileging semaglutide and tirzepatide as first-line therapy across most obesity complications. The choice between them is no longer 'whichever your insurance covers' — it now depends on which complications you have.
GLP-1s After 65: Efficacy, Muscle Loss, and Cardiovascular Outcomes in the New Data
Two ECO 2026 senior-population analyses — Padova's STEP pool on semaglutide 2.4 mg and Lilly's ATTAIN pool on orforglipron — finally fill a clinical gap that's existed since Wegovy launched. Here's how to read them, where the data still falls short, and what it means for prescribing in adults over 65.
How to Stay Off GLP-1s: The 2026 Maintenance Playbook
The May 12 SURMOUNT-MAINTAIN (Lancet) and ATTAIN-MAINTAIN (Nature Medicine) dual publication finally gives prescribers Phase 3 evidence for what happens when patients step down from injectable GLP-1s. Spoiler: with the right protocol, most of the weight loss stays. Without it, two-thirds comes back.
Wegovy Across Menopause: The May 2026 Data for Women in Their 40s and 50s
A new STEP UP post-hoc analysis and a 34,000-woman real-world database, both presented at ECO 2026, finally answer the question many perimenopausal women have been asking: does this drug work the same way during the hormonal transition? Plus a SELECT subgroup result on cardiovascular events that's bigger than the population average.
Beyond Weight Loss: 8 Non-GLP-1 Peptides Tackling Rare Disease in 2026
While the obesity drugs eat the headlines, a second-tier pipeline of peptide therapeutics is doing real work in indications most patients have never heard of. Post-bariatric hypoglycemia, hypothalamic obesity, oral PTH for osteoporosis, oligonucleotide conjugates for DM1. Here's what's actually in the clinic and what the next 18 months look like.
AI-Designed Cyclic Peptides Are Cracking Undruggable Targets
In the last four weeks: CIP-3 hit nanomolar CD28 antagonism from an AI design pipeline, CycloSEL screened 16 million macrocycles to nail a WDR5 inhibitor, Merck published a biocatalytic synthesis that cuts oral PCSK9 step count by more than half. The cyclic-peptide drug-discovery stack just changed. Here's what's actually new.
Tired on a GLP-1? Why Retatrutide Hits Harder and What Helps
Fatigue affects 5–11% of GLP-1 users in trials — Ozempic, Wegovy, Mounjaro, Zepbound included — and retatrutide's glucagon-receptor activity gives it a different fatigue profile from the rest. Here's what's mechanism, what's calorie deficit, and what's a sourcing problem in disguise.
What's Next After GLP-1: 6 Peptide-Receptor Systems Driving the Next Decade of Obesity Drugs
An April 10, 2026 Frontiers in Drug Discovery review and a companion Bloomgarden commentary in Journal of Diabetes have laid out the post-incretin research agenda. The candidates: apelin, spexin, phoenixin, relaxin-3, osteocalcin, irisin. Plus Stanford's BRP and a few others. Here's what's actually credible.
Tweaked Your Back? Tore Something Snowboarding? What Peptides Can and Can't Do for Injury Recovery
BPC-157, TB-500, and the Wolverine Stack get pitched as a recovery cheat code. The animal data is real, the human evidence is thinner than the marketing suggests, and the regulatory ground keeps moving.
Peptide Blends vs. Separate Vials: KLOW, Glow, and Wolverine Without the Marketing
A blend is cheaper per milligram and easier to reconstitute. It also locks your ratio, hides which component caused the welt, and has zero published stability data. When the blend math works, when it doesn't, and what experienced users actually do.
April 2026 in Peptides: The Month That Reset the Industry
Foundayo's launch, the FDA Category 2 removal, Lilly's $19.8B quarter, AACR peptide oncology, and a 503B compounding proposal all in 30 days.
Peptides vs. Growth Hormone (HGH): Why the Pituitary Pathway Isn't the Same as Direct Injection
Sermorelin, CJC-1295, ipamorelin, tesamorelin, MK-677 push your pituitary to release GH. Recombinant HGH skips it entirely — that gap drives the differences.
CGRP and Migraine: The Peptide Drug Class Most Peptide-Curious People Have Never Heard Of
Eight FDA-approved drugs target the CGRP peptide. Anti-CGRP antibodies halve monthly migraine days for 30-49% of patients — peptide drug class most fans miss.
Peptides for Sleep: The RCT Evidence on DSIP, Epitalon, and Semax
MK-677 boosts slow-wave sleep 50%. Three orexin antagonists are FDA-approved. DSIP — the peptide literally named for sleep — has almost no modern data.
Peptides for Gaining Weight: Lean Mass, Appetite, and the Underweight Patient
Peptides for weight gain in the underweight, post-illness, and post-GLP-1 patient: the appetite and IGF-1 effects others call side effects are the mechanism.
Blood Work Before and After Peptides: The Panels That Show Whether Yours Is Working
A peptide-by-peptide guide to blood work, body comp scans, and questionnaires that make a subjective protocol measurable: IGF-1, HOMA-IR, DEXA, CD4:CD8, PHQ-9.
Peptides for Anxiety, Panic, and Stress: Where the Evidence Lands
Selank has RCT data vs. benzos. Oxytocin can paradoxically raise anxiety. GLP-1s show big anxiolytic signals in observational data — state of the 2026 evidence.
Peptides for Chronic Gut Issues: IBD, IBS, Leaky Gut, and the Evidence Hierarchy
Four peptides are FDA-approved for gut conditions. BPC-157 — the one everyone asks about — has a Phase 2 UC trial that was completed and never published.
Peptides for Fertility and IVF: The Clinical Evidence in 2026
Modern IVF runs on peptides. GnRH analogs power every cycle, and kisspeptin triggers may eliminate OHSS risk for high-risk patients. State of the field in 2026.
Peptides for Long COVID, ME/CFS, and Post-Viral Fatigue: The Evidence Map
Clinics prescribe peptides for post-viral fatigue. NIH RECOVER doesn't. The gap between peptide rationale and evidence is wider than the marketing suggests.
Peptides for MCAS and POTS: The Mast Cell and Autonomic Cluster
MCAS and POTS co-occur in 66% of cases. Best peptide signal: a 47-patient GLP-1 series. Some peptides release histamine and flare what you're treating.
Peptide-Drug Conjugates: The Quiet Revolution in Targeted Cancer Therapy
Two FDA-approved drugs, 50+ in trials, and a $1.5B market by 2031 — PDCs are finally having their moment.
The Muscle-Preservation Race: Trevogrumab, Bimagrumab, Apitegromab, and the Pharmacology of Keeping Lean Mass on GLP-1s
About a third of GLP-1-induced weight loss is lean mass. Four drugs targeting the myostatin/activin pathway are now in obesity trials. COURAGE, BELIEVE, and EMBRAZE have produced the first Phase 2 readouts. What the data shows, how the mechanisms differ, and why the FDA is raising the bar.
Peptides for Acne-Prone and Post-Acne Skin: The Evidence Map
Antimicrobial peptides kill Cutibacterium acnes in preclinical studies — but the real clinical wins for peptides in acne are on the aftermath: post-inflammatory hyperpigmentation, scar remodeling, and barrier repair. Here's the honest breakdown of mechanism vs. clinical evidence.
Peptides for Arthritis: What Actually Works, What's Still Preclinical, and What the Hype Gets Wrong
GLP-1 knee-osteoarthritis data is the strongest peptide-arthritis evidence in 2026. PEPITEM matched infliximab in mice. BPC-157 and TB-500 have one retrospective study between them. The peptide-for-arthritis story, mapped against the clinical evidence.
Eating Enough Protein — and Training Hard Enough — on GLP-1s
A San Raffaele study tracking 332 adults found that GLP-1 users consume just 0.6 g/kg/day of protein — 88% fall below even conservative guidelines. The muscle-loss data, the protein math, and why resistance training isn't optional.
Flushing After CJC-1295 or Ipamorelin: What the Studies Can Explain
The available research does not prove a single cause for flushing after a CJC-1295/ipamorelin blend or establish a predictable harmless course.
GHK-Cu Stinging and Welts: Evidence Limits and When to Seek Care
Copper and mast-cell experiments do not establish a universal explanation for reactions to GHK-Cu injections. Skin-care findings cannot establish injectable safety.
Why So Many People Quit GLP-1 Drugs — And How to Stay on Track
In one insurance-claims study, fewer than 1 in 4 patients stayed on a GLP-1 drug for a year, and in the STEP 1 extension people regained two-thirds of their lost weight within a year of stopping. Why people quit, what happens when they do, and practical ways to stay on track.
Tanning Peptides: Melanotan I vs Melanotan II Across Efficacy, Safety, and Regulatory Status
One is FDA-approved with 1,000+ patients and zero melanomas. The other is an unlicensed TikTok trend linked to melanoma case reports. They share a name and a receptor — but almost nothing else.
Transitioning From Semaglutide/Tirzepatide to Retatrutide: The Data, the Reddit Reports, and the Dosing Gaps Between Them
Retatrutide is a reset, not a continuation. Here's what the Phase 3 evidence, pharmacology, and community transition patterns say about sequencing the triple agonist after semaglutide or tirzepatide.
GLP-1 Drugs and Addiction: Can Ozempic Curb Alcohol, Opioids, and More?
A landmark study of 606,000 veterans found GLP-1 drugs reduced new substance use disorders by 14-25% and overdose deaths by 50%. From alcohol to opioids to cannabis, the reward-pathway science is catching up to what patients have been reporting for years.
When Do GLP-1 Patents Expire? The Complete Generic Timeline
Generic semaglutide is already sold in Canada, India, and Brazil, generic liraglutide has been on US shelves since 2024, and tirzepatide's main US patent runs to May 2036. When each GLP-1 drug can go generic in the US, and what that means for cost.
Peptides and Sports: Which Ones Will Get You Banned
From CrossFit to UFC, athletes are catching multi-year bans for peptides like BPC-157, CJC-1295, and TB-500. Here's exactly what WADA prohibits, who's been caught, and what competitive athletes need to know.
The Peptide Quality Crisis: What Investigations Found and How to Protect Yourself
Within two weeks in April 2026, ProPublica, The New Yorker, The Guardian, NBC News, and regulators in three countries reached the same conclusion: a lot of what people are injecting isn't what's on the label.
Peptides and the Menstrual Cycle: Timing, Side Effects, and Hormonal Interactions
GLP-1 nausea is worse when estrogen peaks. GH secretagogue response varies by cycle phase. Kisspeptin sensitivity shifts across the month. Here's what the science says about how peptides interact with the menstrual cycle.
The Peptide Skin-Brightening Lineup: Glutathione, Nonapeptide-1, Oligopeptide-68, and Decapeptide-12
Hydroquinone, kojic acid, and arbutin dominate the hyperpigmentation market — but a new generation of peptides targets melanin synthesis at four different points in the pathway, often with far better safety profiles. Here's what the clinical evidence actually shows for each.
Looksmaxxing Peptides: The Evidence Behind the Aesthetic Optimization Trend
From Retatrutide body recomposition to GHK-Cu skin protocols, peptide stacks have become the backbone of the looksmaxxing movement. We break down what the science actually supports — and where the hype runs ahead of the data.
Peptide Stacking with GLP-1s: What People Are Combining with Ozempic and Mounjaro
Evidence for an individual peptide does not establish that adding it to semaglutide or tirzepatide improves muscle, gastrointestinal symptoms, or skin outcomes.
Peptides for Running, Cardio, and Endurance: Recovery, Performance, and the Evidence Map
From BPC-157 for tendon injuries to MOTS-c for mitochondrial performance, runners are turning to peptides for an edge. Here's what actually has data behind it — and what's still a bet on animal studies.
Foundayo vs Oral Wegovy: The Battle of the GLP-1 Pills
Eli Lilly's small-molecule pill vs Novo Nordisk's peptide tablet. One is more convenient, the other more effective. Here's what the data shows — and why no head-to-head trial exists yet.
Peptide Injection Reactions: Histamine, Allergy, and the Evidence
Injection reactions can have different causes. Laboratory mast-cell findings do not establish which mechanism caused a particular reaction or whether continuing injections is safe.
Oral vs Injectable Peptides: Foundayo's Approval Reshapes the Delivery Debate
Eli Lilly's oral GLP-1 pill eliminates injections entirely. Here's how oral and injectable peptide delivery compare — and why the future of peptide therapy may be swallowed, not injected.
The Most Popular Peptides of 2026
From oral GLP-1 pills and triple agonists to the FDA reclassification saga and a copper peptide going viral — what's driving 10 million monthly peptide searches.
Will Peptides Work for Me? What Genetics, Sex, and Phenotype Tell Us
A landmark 2026 Nature study of 27,885 people found genetic variants that predict GLP-1 drug response. But genetics is just one piece — here's the full picture of why peptides work differently for different people.
Weight Loss Peptides and Muscle Loss: The Problem, the Science, and How to Protect Lean Mass
GLP-1 drugs produce dramatic fat loss — but 25-40% of weight lost is muscle. New combinations like bimagrumab + semaglutide and next-gen drugs like retatrutide may change that equation.
GLP-1 Drugs and Emotional Flattening: What We Know and Don't Know
Reports of emotional change raise questions that reward-circuit studies and depression questionnaires cannot answer on their own. Here is what the cited research actually measured.
Supplements That Stack Well with Peptides: An Evidence-Based Guide
From creatine for GLP-1 muscle preservation to zinc for thymic peptides and magnesium for sleep-stack GH protocols — what the research supports.
Peptide Legality in 2026: FDA Status, Compounding, and the RFK Reclassification
The regulatory landscape for peptides is shifting fast. Here's what's actually changed, what's still pending, and how to legally access peptide therapy in 2026.
Ozempic Alternatives in 2026: Compounded Semaglutide, New Drugs, and What to Know
Brand-name GLP-1 drugs cost $1,000+/month. Here's a research-backed look at compounded semaglutide, tirzepatide, oral options, and what's coming next.
Peptides for Women: The Research Across Menopause, Fertility, Skin, and Bone
From FDA-approved sexual health treatments to weight loss, skincare, and fertility — a research-backed look at which peptides have been studied in women and what the evidence says.
Best Peptides for Muscle Growth: The 2026 Evidence Map
GH secretagogues, IGF-1 variants, and recovery peptides can support lean mass — but the effects are modest compared to steroids. Here's the honest breakdown.
Peptides vs Steroids: A Complete Comparison
Peptides and anabolic steroids are fundamentally different — in mechanism, safety, legality, and what they can realistically achieve. Here's what the evidence shows.
Peptides for Hair Growth: GHK-Cu, TB-500, and the Research Behind Them
Copper peptides lead the evidence for peptide-based hair regrowth. Here's what's proven, what's promising, and what's hype.
LL-37 and the Antimicrobial Peptide Frontier
As antibiotic resistance grows, host defense peptides like LL-37 are being studied as a fundamentally different approach to fighting infection.
BPC-157 and Gut Healing: What Human and Animal Studies Show
BPC-157 has extensive preclinical literature and a few small human reports. Those human reports do not establish efficacy for gastrointestinal disease or long-term safety.
The Evidence Gap: Which Popular Peptides Have Almost No Human Data?
A frank look at the disconnect between online popularity and clinical evidence for some of the most popular peptides.
GLP-1 Agonists Beyond Weight Loss
What 100+ clinical trials reveal about semaglutide, tirzepatide, and the next generation of incretin therapies — from cardiovascular protection to neurodegeneration.
The Mitochondrial Peptide Revolution
MOTS-c, SS-31, and Humanin are rewriting our understanding of aging at the cellular level. Here's what the research actually shows.
MK-677: The Oral Growth Hormone Secretagogue With 15 RCTs
One of the most studied non-injectable peptide mimetics — what the clinical trial evidence shows about sleep, muscle, bone, and the IGF-1 axis.
Neuropeptides in 2026: The State of Research Across CGRP, Oxytocin, Substance P, and Orexin
Semax, Selank, Cerebrolysin, and Dihexa — separating clinical evidence from online hype in the cognitive enhancement space.
Tesamorelin: From HIV Lipodystrophy to Liver Health and Cognitive Enhancement
How a growth hormone-releasing peptide with 20+ RCTs became one of the most evidence-backed peptides in clinical medicine.
Thymic Peptides and Immune Restoration
Thymosin Alpha-1, Thymalin, and Thymulin — how thymus-derived peptides are being studied to combat immunosenescence and age-related immune decline.